Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 120   

Articles published

JNJ 103.36 -0.37 (-0.36%)
price chart
Is It Time to Buy Johnson & Johnson's Stock?
A common belief among investors is that it can be considerably tougher for megacap blue-chip companies to double compared to small-caps stocks.
Related articles »  
Johnson & Johnson to Seek Buyer for Cordis Medical-Device Unit
The sales process for the business, called Cordis, is at an early stage, the people said. The business, which could fetch between $1.5 billion and $2 billion, is expected to attract interest from private-equity firms and other health-care companies ...
Johnson & Johnson Said Exploring Sale of Cordis Devices Business  Bloomberg
Johnson & Johnson to seek buyer for medical device maker unit: WSJ  Reuters
Related articles »  
Update: Johnson & Johnson Received FDA's Class I Label For Jaw-Stabilizing ...
The FDA has put its highest-risk Class I label on the recall of Johnson & Johnson's subsidiary DePuy Synthes' jaw stabilizing system.
Related articles »  
Johnson & Johnson In Trouble Again
Johnson & Johnson (JNJ) is back in the news once again for manufacturing faulty hip implants. This time the company's pinnacle line of surgical hip devices is blamed for poisoning patients.
DePuy Pinnacle Hip Trial Starts Today  Legal Examiner
J&J Readies for Trial Over Hip Implants Blamed for Poisoning Patients  ClaimsJournal.com
Related articles »  
Johnson & Johnson: Moving To Higher-Growth Technologies, Capitalizes On ...
Johnson & Johnson has been a steady dividend income stock with defensive qualities that help protect shareholder returns.
Related articles »  
Bayer/Johnson & Johnson to Expand Xarelto Label Further
The drug is marketed by Johnson & Johnson in the U.S. and by Bayer outside the U.S. Xarelto is approved for several indications including stroke prevention in nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE) and ...
Related articles »  
Johnson & Johnson vs. Abbott Laboratories in the Battle for Emerging Market Turf
Based on my 8 rules of dividend investing (more on that below), Abbott Laboratories has the advantage, but Johnson & Johnson is a fantastic company as well. Both businesses make excellent investments for long-term oriented shareholders seeking rising ...
Related articles »  
3 Reasons Johnson & Johnson Stock Could Rise
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ ) might be a $280-plus billion dollar company, but it's certainly not growing like one as evidenced by the company's robust growth reported in the second quarter.
Related articles »  
Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher
In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Johnson & Johnson (NYSE: JNJ). In the report, Morgan Stanley noted, �We're adjusting our pharma estimates modestly to reflect our changing market ...
Related articles »  
5 Things Johnson & Johnson's Management Wants You to Know
A month ago today healthcare giant Johnson & Johnson (NYSE: JNJ ) reported what looked on the surface to be another stellar quarter of growth.
Robert Wood Johnson's New Industry Made Surgery Safer  Investor's Business Daily
Related articles »